Leverage falls under target but China albumin pressure deepens
- Biopharma made 86.2% of 2025 revenue, showing Grifols is mainly a plasma medicines company.
- Management is cutting cost per liter by scaling Egypt plasma and closing weak U.S. donor centers.
- Total net leverage fell below 4.0x in the third quarter of 2026, marking a major milestone.
- China albumin sales fell 13.2% in the third quarter as excess channel inventory delayed recovery.
- The potential U.S. Biopharma IPO update was pushed to 2027, leaving a key catalyst unclear.
A cleaner operational turnaround held back by the balance sheet
The bull case is that Grifols is finally doing the hard work its balance sheet demanded. It refinanced 2027 maturities, pushed major debt risk out, and keeps improving plasma operations. The Egypt platform is expected to collect about 1 million liters in 2026 and scale to about 3 million liters by 2029. That matters because cheaper plasma can lift margins.
The business demand picture is also solid. Immunoglobulin, the core medicine group, has regained lost U.S. share after the pandemic disruption. Management expects that franchise to grow around a 6% to 8% CAGR, meaning a steady yearly growth rate over time. Recent launches like Fesilty in the U.S. show pipeline progress.
The bear case has not gone away. Grifols still carries a heavy debt load, even though total net leverage dropped to 3.98x in the third quarter. Albumin in China continues to contract, falling 13.2% in the third quarter of 2026 due to high channel inventories. Management also delayed the expected update on the possible U.S. Biopharma IPO to 2027, which leaves a key debt reduction catalyst unclear.
Finn's view fits that mix. Growth is real, valuation is not stretched, but performance and financial health still reflect a company working through past leverage and execution problems.
Plasma in, proteins out
Grifols runs a vertically integrated plasma model. It collects plasma from donors, processes it in factories, and separates it into proteins used as medicines. That separation process is called fractionation.
The key profit lever is cost per liter, or how much it costs to collect each liter of plasma before it becomes medicine. Grifols is moving toward a two-system model. U.S. plasma mainly serves the U.S. market, while Egypt and other non-U.S. sources serve rest-of-world demand. The goal is to stop shipping as much high-cost U.S. plasma into lower-price markets.
Scale helps, but it also raises execution risk. The company had more than 400 plasma collection centers at the end of 2025, then said in early 2026 it had closed 29 underperforming U.S. donor centers with some volume moved to better sites. If collections, yields, or donor economics slip, the margin story weakens fast.
Cash also depends on timing. Plasma collected today can take time to become finished product. That means growth can use cash before it shows up as revenue.
The medicines that drive the model
Immunoglobulins
This is the core franchise, led by Gamunex, Xembify, and Biotest Yimmugo in the U.S. Demand is strong, and management expects the franchise to normalize around a 6% to 8% CAGR.
Subcutaneous IG
Subcutaneous IG is taken under the skin instead of through an IV. Xembify has been a major growth driver because it can be easier for some patients to use at home.
Albumin
Albumin is a large plasma protein business, but China is pressuring prices and channel inventories remain high. That makes it a cash generator with a current headwind.
Alpha-1 therapies
Alpha-1 treatments serve patients with a rare protein deficiency that can damage lungs and liver. The SPARTA readout in late 2026 is a watch item for this franchise.
Fibrinogen
Grifols launched its Fesilty fibrinogen product for congenital indications in the U.S. in mid-2026. The company is seeking FDA agreement on trial design for acquired indications.
Diagnostics
Diagnostics gives Grifols a smaller, steadier business in blood typing and donor screening. The company recently launched the Evansys platform to capture share.
Biopharma carries the company
The mix uses 2025 net revenue from the 2025 Form 20-F. Biopharma is 86.2% of revenue, so changes in immunoglobulin, albumin, and plasma costs matter far more than the smaller units.
What could still break
Debt stays too high
High impact · Medium oddsThe 2026 refinancing removed the near 2027 wall and extended major facilities to the next decade. Total net leverage fell to 3.98x in the third quarter of 2026, but Grifols is not a low-debt company. If EBITDA stalls, leverage can stay too high and keep pressure on the stock.
U.S. Biopharma IPO disappoints
High impact · Medium oddsThe possible IPO of a minority stake in U.S. Biopharma could help debt reduction. The problem is that management pushed the update to 2027 and has not given key details on valuation, timing, governance, or how proceeds would be used. A weak structure could confuse investors instead of helping them.
China albumin pricing pressure lasts
Medium impact · High oddsAlbumin sales are under pressure in China because of government cost controls and high channel inventories. The segment contracted 13.2% in the third quarter of 2026. A longer price reset would hurt revenue mix and margins.
Egypt scale-up misses
Medium impact · Medium oddsThe Egypt plasma platform is central to lowering cost per liter outside the U.S. Grifols targets about 1 million liters in 2026 and about 3 million liters by 2029. Any collection, quality, or logistics issue would slow the margin plan.
New CIDP drugs take share
Medium impact · Medium oddsSome patients with CIDP use immunoglobulin therapy, which is important to Grifols. Novel FcRn inhibitors could compete for those patients. Management has pushed back by saying some patients are switching back to IG, but the threat is real.
Currency and U.S. policy drag EBITDA
Medium impact · Medium oddsA weaker U.S. dollar hurts Grifols when dollar profits are translated into euros. Management said each cent of U.S. dollar depreciation versus the euro has about a EUR 7 million full-year EBITDA headwind. U.S. IRA Part D redesign is another pressure point.
In one breath
What does Grifols actually do?
Grifols collects human plasma and turns it into medicines. Its main products treat immune disorders, albumin needs, Alpha-1 deficiency, and blood clotting problems.
Why does plasma cost matter so much?
Plasma is the raw material for Grifols' main medicines. If the company collects each liter at a lower cost and processes it well, margins can rise.
Is Grifols still risky because of debt?
Yes. The 2026 refinancing reduced near-term refinancing risk, and leverage finally fell below 4.0x. However, the company is still leveraged, and investors should watch free cash flow and proceeds from the possible U.S. Biopharma IPO.
What are the next big catalysts?
The biggest watch items are the 2027 update on the U.S. Biopharma IPO, FDA discussions for acquired fibrinogen indication, and the SPARTA Alpha-1 clinical readout expected in late 2026.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Grifols, S.A. in Finn's Drug Manufacturers - General industry ranking.

